The president of the UCLA Health System, which is still contending with the outbreak of a superbug that infected 7 patients and killed 2, is stepping down from his position for a new appointment as president and chief executive officer of Geisinger Health System.
The president of the UCLA Health System, which is still contending with the outbreak of a superbug that infected 7 patients and killed 2, is stepping down from his position for a new appointment as president and chief executive officer (CEO) of Geisinger Health System.
David T. Feinberg, MD, MBA will succeed Glenn Steele, Jr, MD, PhD. Dr Feinberg, who will join Geisinger May 1, 2015, has been named to Modern Healthcare’s 50 Most Influential Physician Executives.
“It is important to me to not only continue, but also expand Geisinger’s work in patient care, research, education, innovation and community service, and I look forward to continuing Geisinger’s trajectory of achievement upward,” Dr Feinberg said in a statement.
In addition to being CEO of the UCLA Hospital System, he is currently the associate vice chancellor for UCLA Health Sciences in California. He has served many roles with UCLA over the years, including vice chair for clinical affairs in the department of psychiatry and behavioral sciences, and medical director of managed care/outpatient services at the UCLA Neuropsychiatric Institute and Hospital.
Dr Feinberg has been named Medical Center CEO of the Year by The Los Angeles Business Journal and Outstanding Physician of the Year by the Southern California Psychiatric Society and won many other awards, as well as authored numerous articles and chapters. He specializes in psychiatry and child psychiatry.
Dr Steele will continue as chairman of xG Health Solutions, a venture of Geisinger that helps healthcare organizations create value and improve quality.
“It has been my extraordinary privilege to lead the organization from a highly respected regional provider to a nationally recognized system,” he said. “I wish Dr. Feinberg well as he continues to build upon Geisinger’s unique position, history and track record of success well into the future, and I will do all I can to help him transition to his new position.”
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Understanding How Fitness Affects Digestive Diseases
April 18th 2025Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.
Read More
FDA Greenlights Dupilumab for Chronic Spontaneous Urticaria, Marking First Approval in a Decade
April 18th 2025Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives and itching remain uncontrolled by antihistamines.
Read More